EMA Withdrawn: LeukoScan (sulesomab) — Immunomedics GmbH

View source ↗

Summary

EMA withdrawn LeukoScan (sulesomab) from Immunomedics GmbH; previously indicated for osteomyelitis and radionuclide imaging.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis

Drugs mentioned

• Leukoscan (Technetium-99m-sulesomab)

Snippet

Status: Withdrawn. Therapeutic area: Osteomyelitis;Radionuclide Imaging. MAH: Immunomedics GmbH. Decision date: 18/01/2017